PredOmix Technologies Pvt. Ltd. has joined hands with National Center for Cell Science (NCCS) (Pune), IIT (Indore), and Bharat Biotech International Ltd (Hyderabad). to develop a new immunotherapy forCoVID-19infection. Supported by the Council of Scientific and Industrial Research, the aim of this program is to generatehuman monoclonal antibodies for the treatment of COVID-19 patients. These antibodies will work by neutralizing the virustocurtail the infection on one hand, and also boost immunity on the other. Work has been initiated in a fast track mode. Partners of this program have come together in the spirit of addressing a public cause, and the goal is to have the therapeutic antibodies available in the next six months. Read more information related to the project.